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Since 1955, several alkyl- carbamates have been developed for the treatment of anxiety 
and epilepsy, including meprobamate, flupirtine, felbamate, retigabine, carisbamate, 
and cenobamate. They have each enjoyed varying levels of success as antiseizure 
drugs; however, they have all been plagued by the emergence of serious and some-
times life- threatening adverse events. In this review, we compare and contrast their 
predominant molecular mechanisms of action, their antiseizure profile, and where 
possible, their clinical efficacy. The preclinical, clinical, and mechanistic profile of 
the prototypical γ- aminobutyric acidergic (GABAergic) modulator phenobarbital is 
included for comparison. Like phenobarbital, all of the clinically approved alkyl- 
carbamates share an ability to enhance inhibitory neurotransmission through modula-
tion of the GABAA receptor, although the specific mechanism of interaction differs 
among the different drugs discussed. In addition, several alkyl- carbamates have been 
shown to interact with voltage- gated ion channels. Flupirtine and retigabine share an 
ability to activate K+ currents mediated by KCNQ (Kv7) K+ channels, and felbamate, 
carisbamate, and cenobamate have been shown to block Na+ channels. In contrast to 
other alkyl- carbamates, cenobamate seems to be unique in its ability to preferentially 
attenuate the persistent rather than transient Na+ current. Results from recent rand-
omized controlled clinical trials with cenobamate suggest that this newest antiseizure 
alkyl- carbamate possesses a degree of efficacy not witnessed since felbamate was 
approved in 1993. Given that ceno- bamate's mechanistic profile is unique among the 
alkyl- carbamates, it is not clear whether this impressive efficacy reflects an as yet 
undescribed mechanism of action or whether it possesses a unique synergy between 
its actions at the GABAA receptor and on persistent Na
+ currents. The high efficacy 
of cenobamate is, however, tempered by the risk of serious rash and low tolerability 
at higher doses, meaning that further safety studies and clinical experience are needed 
to determine the true clinical value of cenobamate.
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1 |  INTRODUCTION
The discovery in 1951 of the dicarbamate meprobamate as 
a new anxiolytic that also possessed antiseizure activity1 
triggered the search for new central nervous system (CNS)- 
active carbamate compounds,2- 6 finally resulting in the dis-
covery of the dicarbamate felbamate in 1969.6 Since then, 
a total of three alkyl- carbamates (i.e., felbamate, retigabine, 
and cenobamate) have been approved for treatment of epi-
lepsy (Figure 1), making alkyl- carbamates one of the most 
successful chemical classes in the history of antiseizure drug 
(ASD) development. Another alkyl- carbamate, carisbamate, 
received provisional approval from the US Food and Drug 
Administration (FDA) in 2008, but this was withdrawn in 
2010 because of inconsistent efficacy across different clini-
cal trials in patients with drug- resistant focal epilepsy.7 
Nonetheless, in 2012, carisbamate received an orphan drug 
designation for the management of infantile spasms and is 
currently in clinical development for therapy of Lennox– 
Gastaut syndrome.8
Cenobamate, the most recent drug of the series of alkyl- 
carbamates developed for epilepsy therapy, showed remark-
able antiseizure efficacy in clinical trials, suggesting that 
this novel ASD brings substantial promise for patients with 
focal seizures that have been difficult to control with other 
medications, and with the potential for freedom from sei-
zures.9 However, impressive clinical efficacy was also de-
scribed for felbamate shortly after its approval in 1993 for 
the management of focal seizures and Lennox– Gastaut syn-
drome.10 Within 1 year, ~120,000 people had been exposed 
to felbamate. Unfortunately, this extensive postapproval use 
revealed a previously unknown risk of life- threatening idio-
syncratic adverse events (aplastic anemia and hepatic failure) 
not seen in preapproval studies,11 which led to a dramatic 
reduction in its use. For experienced pharmacologists and 
toxicologists, these idiosyncratic adverse events of felbamate 
were not entirely surprising, because induction of aplastic 
anemia was previously reported for the structurally similar 
alkyl- dicarbamate meprobamate.11,12 In a later development, 
a new type of adverse effect (i.e., blue skin discoloration and 
pigment changes in the retina) was reported for retigabine, 
leading to its withdrawal in 2017.13
The aim of this review is to critically discuss the “ups and 
downs” of alkyl- carbamates in epilepsy therapy. Are they 
all the same, or do they differ in their pharmacology, toxi-
cology, and clinical efficacy? Is cenobamate really a “game 
changer,”9 or is it too early to assess its efficacy, tolerability, 
and safety? Finally, with the evolving era of precision med-
icine for rare monogenetic epilepsies, will alkyl- carbamates 
such as retigabine and carisbamate attract renewed interest? 
We briefly review each of the alkyl- carbamates shown in 
Figure 1; compare their preclinical efficacy in animal seizure 
and epilepsy models, mechanisms of action, clinical efficacy, 
and safety; and finally, discuss additional alkyl- carbamates in 
the preclinical pipeline.
2 |  ALKYL - CARBAMATES WITH 
PRECLINICAL AND CLINICAL 
ANTISEIZURE EFFECTS
2.1 | Meprobamate
Meprobamate, a carbamylated derivative of propanediol (2- m
ethyl- 2- propyl- 1,3- propanediol dicarbamate; Figure 1), was 
introduced as an antianxiety drug in 1955. It was the first drug 
to be used as an anxiolytic agent; it was also used as a sedative– 
hypnotic and, less frequently, as an ASD. Meprobamate was 
developed by Frank Berger at Wallace Laboratories, a di-
vision of Carter Products (later Carter- Wallace; Cranbury, 
New Jersey) in the early 1950s, based on previous experience 
with the sedating or “tranquilizing” effect of mephenesin in 
rodents.14 The report of Berger14 marked the beginning of 
investigations of modern sedatives with useful antianxiety 
and minor tranquilizing properties. After its approval, me-
probamate rapidly became the first blockbuster psychotropic 
drug in American history,15 but it was later largely replaced 
by the benzodiazepines (BDZs) due to their wider therapeu-
tic index. In addition to its anxiolytic and sedative effects, 
meprobamate exerts antiseizure activity in animal models 
(see below) and epilepsy patients. Meprobamate appears to 
act by modulating the γ- aminobutyric acid type A (GABAA) 
receptor via a barbiturate- like action,16 but other mechanisms 
may contribute to its pharmacology (see below for more 
detailed discussion). Based on its GABAergic effect, me-
probamate has abuse potential and may induce dependence 
Key Points
• Alkyl- carbamate drugs have efficacy in experi-
mental models of seizures and epilepsy and in the 
clinical management of seizure disorders
• Two classes of alkyl- carbamates exist; dicarba-
mates (e.g., felbamate) and monocarbamates (e.g., 
retigabine, carisbamate, cenobamate)
• Most alkyl- carbamates act as positive allosteric 
modulators of the GABAA receptor and enhance 
inhibitory neurotransmission
• Most also possess additional modes of action, 
including effects on voltage- gated Na+ and K+ 
channels and on ionotropic glutamate receptors
• In addition to their recognized clinical efficacy, 
alkyl- carbamates have often been associated with 
serious adverse reactions
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with continued use; it is a Drug Enforcement Administration 
(DEA) Schedule IV controlled drug in the United States (as is 
the anticonvulsant and sedative/hypnotic drug phenobarbital, 
which also mainly acts via the GABAA receptor). The major 
unwanted effects of the usual sedative doses of meprobamate 
are drowsiness and ataxia. However, soon after its approval, 
meprobamate was reported to induce potentially fatal aplas-
tic anemia as a rare idiosyncratic adverse effect.11,12 That 
aplastic anemia was later also associated with felbamate (see 
below) may indicate that this severe adverse event is a class 
effect of dicarbamate esters of propanediol.
2.2 | Felbamate
Felbamate (2- phenyl- 1,3- propanediol dicarbamate) was syn-
thesized and developed by Wallace Laboratories in the 1950s 
as part of their efforts to explore structure– activity relation-
ships with meprobamate.6,17 As shown in Figure 1, felbamate 
is a close structural analogue of meprobamate, both being 
dicarbamate esters of propanediol. In contrast to meproba-
mate, however, felbamate lacked pronounced tranquilizing 
or sedative activity, so it did not receive much attention until 
approximately 30 years later, when Wallace Laboratories 
submitted felbamate to the Epilepsy Branch of the National 
Institute of Neurological Disorders and Stroke (NINDS) for 
anticonvulsant screening.18 Felbamate's antiseizure profile 
was similar to that of phenobarbital and valproate. Later 
studies indicated that felbamate, similarly to meprobamate 
(and phenobarbital), enhances GABAergic neurotransmis-
sion at the GABAA receptor, but it also blocks the N- methyl- 
D- aspartate (NMDA) subtype of glutamate receptors and 
voltage- dependent Na+ channels.19 In contrast to meproba-
mate (and phenobarbital), felbamate is not listed in the DEA 
Schedules, possibly as a result of its lower potency in mod-
ulating the GABAA receptor (see more detailed discussion 
below). Based on its promising preclinical profile and posi-
tive findings in regulatory trials, felbamate was approved in 
1993 for the treatment of focal seizures (with or without gen-
eralization) in adults and for focal and generalized seizures 
associated with Lennox– Gastaut syndrome in children.20 It 
was the first drug shown to be effective in treating Lennox– 
Gastaut syndrome in controlled trials.21 In its first year on the 
market, felbamate reached an estimated patient population of 
120,000, but soon after its introduction, it was associated with 
multiple cases of aplastic anemia and acute liver failure, and 
its use has been restricted ever since.10,22 A total of 31 cases 
of aplastic anemia and 18 cases of hepatic failure were re-
ported following approval of the drug in the United States.23 
Risk of aplastic anemia in patients who take felbamate is be-
lieved to be between 27 and 209 cases per million, with the 
most probable risk estimate being 127 cases per million.22 
The mechanism of these rare idiosyncratic adverse effects is 
unknown, but they are likely to be due to bioactivation of fel-
bamate to a highly reactive electrophilic toxic metabolite.24 
Although felbamate is not indicated as first- line antiseizure 
therapy, its utility in treating patients with severe epilepsy 
who have inadequately responded to alternative drugs is un-
disputed.22,23 Furthermore, there are certain precautions that 
can minimize the risk of serious adverse reactions associated 
with felbamate (see the section Risk of Severe Idiosyncratic 
Adverse Events With Different Alkyl- Carbamates), thereby 
providing an option in refractory cases where no other drug 
works.22,25
F I G U R E  1  Alkyl- carbamates with 
antiseizure activity. Note that meprobamate 
and felbamate are dicarbamates, whereas 
the other drugs are monocarbamates
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2.3 | Flupirtine
The centrally acting analgesic and muscle relaxant flupirtine 
(N- [2- amino- 6- [(4- fluorophenyl)methylamino]- 3- pyridinyl]
carbamic acid ethyl ester; Figure 1) was developed in the 1970s 
and 1980s by Chemiewerk Homburg (later ASTA Medica, a 
branch of the Degussa group) in Germany in close coopera-
tion with its US partner Carter- Wallace Laboratories.26- 29 It 
has been marketed since 1984 in European countries as an 
effective, nonopioid, non- nonsteroidal anti- inflammatory 
drug (non- NSAID) analgesic for the management of acute, 
moderate- to- severe cases of pain.30 The antiseizure effects 
of flupirtine were also evaluated within the NINDS- funded 
Anticonvulsant Screening Program at the University of Utah 
by the group of Ewart A. Swinyard.26 Flupirtine was reported 
to exert antiseizure effects in animal models of epilepsy and in 
a pilot study in patients with refractory seizures.26 It was shown 
to act as an opener of voltage- dependent KCNQ (Kv7) potas-
sium channels and as a GABAA receptor modulator,
29,31 and 
was the first KCNQ opener in therapeutic use, introduced long 
before retigabine.29 However, following its widespread use as 
an analgesic, flupirtine was reported to cause rare but occasion-
ally fatal liver injury, leading to restrictions on its use.13 Clinical 
trials with flupirtine in patients with epilepsy were discontinued 
due to the development of a more potent (and reportedly less 
toxic) analogue, retigabine (ezogabine). Recently, however, in-
terest in the antiseizure activity of flupirtine has been reignited 
because of studies indicating that it is more effective than either 
of two commonly used ASDs, phenobarbital and diazepam, in 
suppressing neonatal seizures and status epilepticus in rats.32- 35 
Furthermore, a combination of flupirtine and diazepam was 
shown to be effective in terminating established (BDZ resist-
ant) status epilepticus in three adult rat models.36
2.4 | Retigabine (ezogabine)
As shown in Figure 1, retigabine (known as ezogabine in 
the United States) is a close structural analogue of flupirtine. 
Unlike the branched dicarbamates felbamate and meproba-
mate, retigabine (N- [2- amino- 4- (4- fluorobenzylamino)phenyl]
carbamic acid ethyl ester) is a monocarbamate compound. In 
the early 1990s, molecular modeling studies at ASTA Medica 
(Frankfurt, Germany), including quantitative structure– activity 
studies and pharmacophore modeling, resulted in the develop-
ment of a number of desazaflupirtine derivatives with anticon-
vulsant activity superior to that obtained with flupirtine.37 The 
most potent of these derivatives was D- 20443, the dihydrochlo-
ride of retigabine, which was subsequently developed as the 
free base (D- 23129 or retigabine) due to technological reasons 
and a superior impurity profile.38 Retigabine exerted a broad 
spectrum of antiseizure activities in animal models.38 One of 
the first studies to investigate a potential mechanism of action 
for retigabine reported that de novo synthesis of GABA within 
the hippocampus was increased by retigabine,39 although this 
was later called into question.40 Subsequent studies showed 
that retigabine, similar to other alkyl- carbamates, potentiates 
GABA- induced currents in rat cortical neurons through a non- 
BDZ binding site mechanism.41 Most likely as a result of its 
effects on GABAA receptors, retigabine is a DEA Schedule V 
controlled substance (substances in the DEA Schedule V have a 
low potential for abuse relative to substances listed in Schedule 
IV). Interestingly, in the prescribing information of retigabine 
(Potiga) provided by GSK, drug effects such as euphoria- type 
and drunken- like subjective responses were described for pa-
tients treated with retigabine, which could be a consequence 
of the GABAergic component of this drug. Furthermore, 
withdrawal symptoms are observed upon discontinuation of 
retigabine in animal studies. In rats, abrupt discontinuation 
of chronic oral administration of retigabine (at either 3, 10, or 
30  mg/kg/day over 28  days) induced behavioral alterations, 
such as piloerection, increases in high step gait, and tremors, 
that were mild and also distinct from the more prominent with-
drawal signs induced by chronic administration of a BDZ.42 
Nevertheless, these data suggest that retigabine produces a 
withdrawal syndrome indicative of physical dependence, which 
is important because such a withdrawal syndrome is a typical 
class effect of drugs that potentiate GABAergic transmission.
In addition to its effects on GABAergic inhibitory trans-
mission, retigabine acts as an opener of K+ channels in neu-
ronal cells,43,44 a mechanism that is thought to be mainly 
responsible for its antiseizure activity (but see more detailed 
discussion below). The effect of retigabine on K+ channels is 
characterized by activation of the KV7 class of voltage- gated 
K+ channels. It is specific for channels containing KV7.2 to 
KV7.5 subunits, and has particular affinity for channel assem-
blies containing dimers of KV7.2/KV7.3 and KV7.3/KV7.5 
subunits.45
Retigabine was originally licensed in the United States 
and Europe in 2011 for the treatment of focal seizures in 
adults.46 Its use was later restricted due to the emergence 
of idiosyncratic adverse effects characterized by blue tissue 
discoloration, and although subsequently withdrawn by the 
manufacturer (GSK), there remains interest in the use of re-
tigabine as a precision therapy in severe epileptic encepha-
lopathies due to mutations in the KCNQ genes.19,47 In 2018, 
Xenon Pharmaceuticals received orphan drug designation for 
treatment of patients with KCNQ2 mutations with retigabine, 
and the company added retigabine to its epilepsy pipeline.
2.5 | Carisbamate
The monocarbamate carisbamate (S- 2- O- carbamoyl- 
1- o- chlorophenyl- ethanol; Figure 1) was initially dis-
covered and developed by the South Korean company 
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SK- Biopharmaceuticals and, in 1998, in- licensed by Johnson 
& Johnson Pharmaceutical Research & Development in the 
United States, who evaluated carisbamate as a novel ASD. 
The compound demonstrated potent antiseizure activity in 
a variety of in vivo seizure models including hippocampal 
and corneal kindling.48 Several potential mechanisms of 
action have been proposed, including use- dependent block 
of Na+ channels, activation of presynaptic Cl− conduc-
tion leading to depression of excitatory neurotransmission, 
and inhibition of voltage- gated Ca2+ channels, but appar-
ently there is no effect on GABAergic transmission.49- 52 
Following several controlled clinical trials with caris-
bamate in patients with refractory focal epilepsy, in 2008 
Johnson & Johnson received provisional approval from the 
FDA to market carisbamate.53 However, carisbamate failed 
to demonstrate consistent efficacy across regulatory trials; 
thus, its new drug application and medical authorization 
application submissions were withdrawn in January 2010, 
and the clinical program in epilepsy was discontinued by 
Johnson & Johnson. In 2012, SK- Biopharmaceuticals, the 
company that initially developed the drug, received an or-
phan designation for the management of infantile spasms 
(West syndrome). Furthermore, SK- Biopharmaceuticals is 
currently performing trials with carisbamate in Lennox– 
Gastaut syndrome.8
2.6 | Cenobamate
As with carisbamate, the monocarbamate cenobamate 
([(1R)- 1- (2- chlorophenyl)- 2- (tetrazol- 2- yl)ethyl] carba-
mate; Figure 1) was discovered and developed by SK- 
Biopharmaceuticals.54 Similarly to other alkyl- carbamates 
reviewed here, cenobamate exerted broad- spectrum antisei-
zure activity in preclinical models.54,55 Cenobamate seems to 
act primarily by two mechanisms (see below for more de-
tailed discussion); it blocks persistent Na+ currents (INaPs) 
and enhances both phasic and tonic GABA inhibition .56,57 
Based on drug discrimination studies, cenobamate was desig-
nated as a Schedule V controlled substance by the DEA, indi-
cating limited physical or psychological dependence relative 
to the drugs in Schedule IV.
On the basis of its marked efficacy in clinical trials in 
patients with therapy- resistant focal epilepsy,9 cenobamate 
was approved in 2019 for this indication in the United 
States. In the first published Phase 2b efficacy study of 
cenobamate for treatment- resistant focal seizures,58 high 
doses produced high seizure- freedom rates, suggesting that 
cenobamate can outperform existing treatment options.9 
However, such high doses of cenobamate were also associ-
ated with a risk of drug rash with eosinophilia and systemic 
symptoms (DRESS) and low tolerability. In a subsequent 
Phase 3, multicenter, open- label safety study in 1339 
cenobamate- treated patients, using a start- low (12.5 mg/d), 
go- slow titration approach, no cases of severe idiosyncratic 
adverse effects (including DRESS) were observed,59 but 
many more exposures are needed to determine the true 
safety profile of the drug.9
3 |  COMPARISON OF 
PRECLINICAL ANTISEIZURE 
EFFICACY OF ALKYL- CARBAMATES 
IN ANIMAL MODELS
For preclinical development of novel ASDs for pharma-
coresistant focal epilepsy, a battery of mouse and rat models 
is used, including the 6- Hz mouse and rat models of drug- 
resistant focal seizures and kindling models, such as amyg-
dala, hippocampal, or corneal kindling in mice and rats.60 
Such a battery of models is also used in the current version 
of the Epilepsy Therapy Screening Program of the NINDS.61 
Furthermore, simple rodent models such as the maximal 
electroshock seizure (MES) test and the subcutaneous pen-
tylenetetrazol (PTZ) seizure test, which have been used over 
decades in ASD screening, are still included in most of the 
current screening programs.60 In addition, simple tests of 
“minimal neurological deficit” such as the rotarod test are 
used to estimate the safety margin (or “protective index”) 
between the median effective dose (ED50) and the median 
neurotoxic dose (TD50).
As illustrated in Tables 1 and 2, the monocarbamates 
retigabine, carisbamate, and cenobamate show compa-
rable efficacies and potencies in rodent seizure models. 
Interestingly, their potency does not appear to decrease 
when increasing the stimulation strength in the 6- Hz mouse 
model from 22 to 32 to 44  mA (Table 1), whereas most 
other ASDs lose antiseizure potency and/or efficacy when 
the current is increased in this test.55,60,62 Furthermore, all 
three drugs were effective in kindled rats, including the 
lamotrigine- resistant amygdala kindling rat model (Table 
2). With respect to safety margins, carisbamate and ceno-
bamate exert antiseizure activity in all models at doses well 
below their TD50, whereas this is not always the case with 
retigabine (Tables 1 and 2).
Only limited seizure model data could be found for mep-
robamate and flupirtine, but the ED50 s of the dicarbamate fel-
bamate in the different models clearly differ from respective 
ED50 s of the three monocarbamates (Tables 1 and 2). The 
most important difference is that felbamate loses antiseizure 
potency with increasing stimulation strength in the 6- Hz test, 
whereas this was not observed with retigabine, carisbamate, 
and cenobamate. Similarly, felbamate is less potent in kin-
dled rats compared to the monocarbamate drugs (Table 2).
The broad antiseizure efficacies of the monocarba-
mates retigabine, carisbamate, and cenobamate differ 
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from most other clinically used ASDs, except for the bar-
biturate phenobarbital, which is shown for comparison in 
Tables 1 and 2. This may indicate that these drugs share 
mechanistic aspects of phenobarbital, which mainly acts 
by potentiating the inhibitory neurotransmitter GABA 
via a barbiturate binding site on the GABAA receptor 
complex.63
4 |  OTHER PHARMACOLOGICAL 
EFFECTS OF ALKYL - CARBAMATES
In addition to antiseizure activity, several alkyl- carbamates 
exert significant disease- modifying or antiepileptogenic ef-
fects in rodent models of epilepsy. For instance, felbamate 
counteracted the development of PTZ kindling in rats,64 












Meprobamate ip 60 127 66 ? ? ? ? 85 Frey and Bartels, 
1997149
Felbamate ip 60 35.5 126 13.1 69.5 241 ? 220 Guignet et al., 202055
Flupirtine po ? 51 39 ? ? ? ? 174 Seaman et al., 198626
Retigabine ip 15 9.3 13.5 ? 26 33 24.1 
(corneal 
kindled)
20.5 Rostock et al., 
199638; Bialer 
et al., 2009150; 
Rowley and 
White, 2010151; 
Bankstahl et al., 
2013152
Carisbamate ip 15 7.9 20.4 20.7 21.4 27.6 ? 46 Bialer et al., 2009150
Cenobamate ip 15 9.8 28.5 11 17.9 16.5 ? 58 Bialer et al., 201354
Phenobarbital ip 30 21.8 13.2 ? 14.8 18.3 9.4
(corneal 
kindling)
69 Barton et al., 200162; 
Bankstahl et al., 
2013152; Koneval 
et al., 2020153
Note:: Phenobarbital is shown for comparison. "?" indicates that no data were found in the public domain.
Abbreviations: ED50, median effective dose; ip, intraperitoneal; MES, maximal electroshock seizure; po, by mouth; PTZ, pentylenetetrazol; sc, subcutaneous; TD50, 
median neurotoxic dose.




ED50, mg/kg Rotarod test, 
TD50, mg/kg ReferencesMES Kindled seizures
Meprobamate ip 60 ? 68
(fully amygdala kindled rats)
? Frey and Bartels, 1997149
Felbamate ip 30 35 296
(fully hippocampal kindled rats)
>500 Guignet et al., 202055
Flupirtine po ? 47 ? 116 Seaman et al., 198626
Retigabine ip 10/30 5.1 3.2 (lamotrigine- resistant fully amygdala 
kindled rats)
10 Rostock et al., 199638; 
Metcalf et al., 2019154
Carisbamate ip/po 15/? 4.4 (po) 22.5 (ip; fully hippocampal kindled rats) 39.5 (ip) Novak et al., 200748; 
Bialer et al., 2009150
Cenobamate ip 15 2.9 16.4 (fully hippocampal kindled rats) 38.9 Guignet et al., 202055
Phenobarbital ip 60 12 16 (fully amygdala kindled rats) 41 Löscher et al., 1986155; 
Löscher and Nolting, 
1991156
Note:: Phenobarbital is shown for comparison. "?" indicates that no data were found in the public domain.
Abbreviations: ED50, median effective dose; ip, intraperitoneal; MES, maximal electroshock seizure; po, by mouth; TD50, median neurotoxic dose.
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and retigabine was the most effective drug in a series of 
compounds at blocking rapid kindling in developing rats.65 
Similarly, carisbamate has been shown to delay amygdala 
kindling in rats66 and to exert powerful disease- modifying 
effects in the lithium- pilocarpine mode,67 but failed to af-
fect epileptogenesis in a rat model of epilepsy precipitated 
by traumatic brain injury.68 At this time, it is not clear 
whether cenobamate possesses any disease- modifying 
activity.
Apart from effects on seizures, meprobamate exerts anx-
iolytic and sedative– hypnotic activities, which formed the 
basis for its clinical use (see above). In contrast, felbamate 
has only minimal anxiolytic and sedative– hypnotic effects at 
therapeutic doses, most likely as a result of its less potent 
effects on the GABAA receptor (see below). Retigabine was 
reported to exert anxiolytic activity in two mouse models of 
anxiety, and its effect in one of these models was blocked 
by the Kv7 channel inhibitor XE- 991,
69 again suggesting this 
as an important mechanism of action of the drug. Similarly, 
cenobamate has been proposed to possess efficacy in mouse 
and rat models of anxiety.54
Another pharmacological effect of alkyl- carbamates is 
their analgesic activity. Analgesia is a class effect of GABA- 
potentiating drugs70- 72 but also of KCNQ activators such as 
flupirtine and retigabine.28,29 Meprobamate is a constituent 
of various combination analgesics and may exert its benefi-
cial activity in such combinations at least in part because of 
its sedative and muscle relaxant properties. Felbamate is ef-
fective in rodent models of acute and chronic pain and against 
neuropathic pain in patients.73- 75 Likewise, flupirtine exerts 
relatively strong analgesic effects in acute and chronic pain 
states in animal models as well as in humans.28,29 Retigabine 
is arguably the most widely studied alkyl- carbamate deriva-
tive in models of nociceptive and neuropathic pain and, to-
gether with its analogue flupirtine (the only alkyl- carbamate 
approved for pain treatment), provided a template for devel-
oping more selective Kv7 openers as analgesic drugs.27,29,76 
In apparent contrast, carisbamate, which had been reported 
to exert an antiallodynic effect in rats,77 did not demonstrate 
efficacy in controlled trials in neuropathic pain.78 Limited 
data exist for cenobamate in this regard, although it has been 
reported to be more efficacious than gabapentin in the spi-
nal nerve ligation (Bennett and Chung) model of neuropathic 
pain.53
As discussed above, most alkyl- carbamates have some 
abuse potential, most likely as a result of their GABAergic 
activity, and are thus DEA Schedule IV (meprobamate) or 
V (retigabine, cenobamate) regulated substances. The ex-
ceptions are felbamate and carisbamate, possibly because 
of lower potency at the GABAA receptor. For comparison, 
phenobarbital and BDZs are Schedule IV regulated drugs be-
cause of their higher abuse liability.
5 |  COMPARISON OF 
MECHANISMS OF ACTION OF 
ALKYL - CARBAMATES
Figure 2 summarizes the main mechanisms of action of alkyl- 
carbamates that may explain their antiseizure effects. A more 
detailed comparison is shown in Table 3, in which pheno-
barbital is included for comparison. Most alkyl- carbamates 
seem to share a phenobarbital- like action on the GABAA re-
ceptor, but other effects may also contribute to their antisei-
zure efficacy.
GABAA receptors are ligand- gated chloride channels 
composed of five subunits that can belong to different sub-
unit classes.79,80 Most synaptic GABAA receptors are com-
posed of two α, two β, and one γ2 subunit and mediate phasic 
inhibition, whereas receptors composed of two α, two β, 
and one δ subunit are predominantly or exclusively located 
extrasynaptically, where they respond to ambient GABA in 
the extracellular milieu and confer tonic (long- term) inhibi-
tion, thereby controlling network excitability. ASDs can be 
differentiated into drugs that potentiate synaptic inhibition 
or extrasynaptic inhibition or both.81 ASDs that potentiate 
both types of GABAergic inhibition (including barbiturates, 
neurosteroids such as allopregnanolone, and several alkyl- 
carbamates) may be more effective in the treatment of acute 
and spontaneous recurrent seizures than drugs that act only 
on synaptic inhibition.81,82
GABAA receptors are the site of action of a variety of 
pharmacologically and clinically important drugs, such as 
BDZs, barbiturates, neuroactive steroids, general anesthetics, 
ethanol, and several convulsant compounds.79,80,83,84 GABA 
acts at orthosteric sites located within the two extracellular 
β+α− interfaces of GABAA receptors, whereas the positive 
allosteric modulation exerted by BDZs involves interaction 
with the extracellular α+γ2− interface and that of barbitu-
rates, neuroactive steroids, ethanol, and general anesthet-
ics seemingly involves interaction with solvent accessible 
pockets in the transmembrane domain of the receptor. In 
contrast, a variety of convulsant drugs such as picrotoxi-
nin and other “cage convulsants” block the chloride chan-
nel of GABAA receptors by binding to a site within the 
channel.79,80 This picrotoxinin binding site on the GABAA 
receptor is typically characterized by the high- affinity li-
gand [35S]t- butylbicyclophosphorothionate (TBPS), a bi-
cyclophosphate derivative with potent picrotoxin- like 
convulsant activity.16,80 A structurally related compound, 
[3H]t- butylbicycloorthobenzoate (TBOB), can also be used 
for this purpose.85 TBPS binding to GABAA receptors can be 
allosterically inhibited by barbiturates, including phenobar-
bital, whereas BDZs, in the absence of GABA, allosterically 
increase TBPS binding in in vitro preparations of rodent and 
human brain.80,86,87 Thus, TBPS (or TBOB) binding is often 
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used as a probe to discriminate drugs acting via BDZ and 
non- BDZ recognition sites at the GABAA receptor.
Meprobamate was the first carbamate for which inter-
actions with GABAergic neurotransmission were report-
ed.16,88- 93 Some early studies suggested that meprobamate 
may bind to the BDZ recognition site of the GABAA recep-
tor,90,91 but this was disputed in other studies.88,89,92 Instead, 
in line with a barbiturate- like action, meprobamate was 
reported to inhibit TBPS binding at the GABAA receptor– 
chloride channel complex16 and to allosterically enhance 
BDZ binding.93 Meprobamate was found to have behav-
ioral actions distinct from BDZs and more characteristic of 
barbiturates,94 although there are also differences between 
meprobamate and barbiturates, both pharmacologically and 
clinically.95 Rho et al.96 reported that meprobamate acts as 
a barbiturate- like positive allosteric modulator (PAM) of 
GABAA receptors, enhancing GABA- evoked responses 
in rat hippocampal neurons and, in the absence of GABA, 
directly activating Cl− currents that could be attenuated by 
the GABAA receptor antagonists bicuculline and picrotoxin. 
Furthermore, the barbiturate antagonist bemegride inhibited 
meprobamate- mediated direct gating of the GABAA recep-
tor in a concentration- dependent manner, consistent with a 
competitive nature of inhibition.97 Meprobamate acts on 
both synaptic and extrasynaptic GABAA receptors.
97 In the 
absence of a selective antagonist for the barbiturate recog-
nition site of the GABAA receptor, it is difficult to pharma-
cologically evaluate the possibility that meprobamate (and 
other alkyl- carbamates) act at the same site on the GABAA 
receptor as barbiturates. However, at high concentrations 
(3  mmol·L– 1), meprobamate did reduce the potentiation of 
GABA currents by 1 mmol·L– 1 pentobarbital, which is com-
patible with the possibility that meprobamate competes for 
binding with pentobarbital (and has lower intrinsic efficacy), 
but may also reflect greater channel- blocking activity of 
meprobamate in comparison with pentobarbital.96 The ef-
fects of meprobamate on GABA- evoked responses, which 
have also been studied in recombinant human GABAA recep-
tors,97 are likely to explain both its antiseizure and anxiolytic/
sedative effects. The channel block of the GABAA receptor 
at high concentrations of meprobamate limits the extent of 
GABA potentiation, making it a less potent CNS depres-
sant than pentobarbital, and may explain the differences 
between meprobamate (and other alkyl- carbamates) and bar-
biturates. In addition to its effects on GABAergic inhibition, 
meprobamate also blocks NMDA- activated currents at high 
(presumably supratherapeutic) concentrations, indicating an 
effect on excitatory glutamatergic activity.96
F I G U R E  2  Presumed mechanisms of action of alkyl- carbamates. The figure has been modified from Löscher and Schmidt147 and Löscher 
et al.148 AMPA, α- amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic acid ; GABA, γ- aminobutyric acid; GAT- 1, GABA transporter 1; KCNQ, 
voltage gated Kv7 potassium channels; NMDA, N- methyl- D- aspartate; SV2A, synaptic vesicle protein 2A
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Felbamate resembles meprobamate in its effects on 
GABAA and NMDA receptors (Table 3) but is a less effec-
tive potentiator of GABAA receptors and does not directly 
activate GABAA receptors in the absence of GABA,
96,98- 100 
likely explaining why felbamate is less sedative than mep-
robamate. The enhancement of GABA- evoked currents by 
felbamate was unaffected by flumazenil, a specific BDZ rec-
ognition site antagonist, indicating that felbamate does not 
act at the BDZ site.98 A 2019 study with competition pho-
tolabeling of recombinant human GABAA receptors indi-
cated that the effects of felbamate on GABA responses do 
not occur by binding at barbiturate interaction sites either.101 
In contrast to meprobamate, felbamate inhibits NMDA re-
ceptors at therapeutically relevant concentrations; however, 
it is uncertain whether the NMDA receptor- blocking activity 
of felbamate is relevant to its clinical antiseizure activity.102 
Single- channel recordings have indicated that the effect 
of felbamate on NMDA responses occurs via a channel- 
blocking mechanism.98 In addition, felbamate has been re-
ported to exert use- dependent block of voltage- gated Na+ and 
Ca2+ channels.19 Overall, the barbiturate- like potentiation of 
GABA by felbamate is the most likely mechanism underlying 
its antiseizure activity, but effects on voltage- gated Na+ chan-
nels may also contribute, particularly to its effects on seizure 
generalization.
Flupirtine at therapeutic concentrations (≤10  µmol·L– 1) 
does not affect voltage- gated Na+ or Ca2+ channels, inward 
rectifier K+ channels, nicotinic acetylcholine receptors, gly-
cine receptors, or ionotropic glutamate receptors in neuronal 
preparations.31 Instead, flupirtine shifts the gating of KV7 K
+ 
channels to more negative potentials and the gating of 
GABAA receptors to lower GABA concentrations, indicat-
ing concomitant facilitation of KV7 channels and GABAA 
receptors.31 In a subsequent study on native and recombinant 
GABAA receptors, Klinger et al.
103 reported that flupirtine 
prefers extrasynaptic δ- containing GABAA receptors over 
synaptic receptors containing the γ- subunit, and also over 
KV7 channels.
Retigabine is thought to act primarily as an opener of 
KCNQ (Kv7) K
+ channels, and several experimental stud-
ies support the role of Kv7  K+ channels in the antiseizure 
activity of this drug.102 Mice with a genetic defect in these 
channels show reduced sensitivity to the antiseizure effect 
of retigabine,104 and the KCNQ inhibitor XE- 991 partially 
blocks the antiseizure effect of retigabine in the mouse 
MES test.104,105 Retigabine exerts no effects on NMDA or 
α- amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic acid 
(AMPA) receptors41,106 and is only a weak inhibitor (half- 
maximal inhibitory concentration [IC50] >100 µmol·L
– 1) of 
voltage- gated Na+ and Ca2+ channels.104 However, as with 
other alkyl- carbamates, retigabine has been reported to in-
teract with the GABA system. At relatively high concentra-
tions (>10 µmol·L– 1), retigabine has been shown to potentiate 
GABA- mediated inhibitory transmission by acting as a PAM 
of GABAA receptors via a non- BDZ site.
41,106 Similar to 
barbiturates (and other alkyl- carbamates), retigabine inhib-
ited TBOB binding to the picrotoxinin site of the GABAA 
receptor in the absence of GABA, indicating that retigabine 
T A B L E  3  Mechanisms of action of alkyl- carbamates with antiseizure activity
Compound
GABA- evoked responses Specific interaction with GABAA receptors Glutamatergic transmission Voltage- gated Na
+ channels
Voltage- gated Ca2+ 
channels








site (TBPS or TBOB 
binding) BDZ recognition site
Receptor activation  
in the absence of  







Meprobamate Enhanced Enhanced Inhibited Allosteric enhancement 
of BDZ binding
Yes Inhibited (only at high 
concentrations)
? ? ? ? ?
Felbamate Enhanced ? Inhibited No inhibition of BDZ 
binding
No Inhibited ? Use- dependent block ? Use- dependent block ?
Flupirtine Enhanced Enhanced ? ? ? No relevant effect ? No effect ? No effect Activated
Retigabine Enhanced Enhanced Inhibited ? ? No effect No effect Weak inhibition ? Weak inhibition Activated
Carisbamate No effect (but see 
text)
? ?
(but effect on picrotoxin- 
sensitive Cl− channels)
? ? Inhibited Inhibited Use- dependent block ? Inhibition ?
Cenobamate Enhanced Enhanced Inhibited No inhibition of BDZ 
binding
? ? ? Little effect (IC50 > 
500 µmol·L– 1)
Block ? ?
Phenobarbital Enhanced Enhanced Inhibited Allosteric enhancement 
of BDZ binding
Yes No effect Inhibited No relevant effect ? Use- dependent block ?
Note:: Phenobarbital is shown for comparison. "?" indicates that no data were found in the public domain. See text for references.
Abbreviations: AMPA, α- amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic acid; BDZ, benzodiazepine; GABA, γ- aminobutyric acid; IC50, median effective dose;  
KCNQ, voltage gated Kv7 potassium channels; NMDA, N- methyl- D- aspartate; TBOB, [3H]t- butylbicycloorthobenzoate; TBPS, [35S]t- butylbicyclophosphorothionate
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interacts with a site on the GABAA receptor complex that is 
positively allosterically coupled with the orthosteric GABA 
binding site.107 Recent evidence that inhibitory effects of 
retigabine on seizure- like activity in hippocampal neurons 
persist in the presence of a blockade of Kv7 channels has 
bolstered the view that positive modulation of GABAA recep-
tors likely makes a significant contribution to its antiseizure 
activity.108 This view is reinforced by the observation that, at 
lower concentrations than those required for effects on syn-
aptic GABAA receptors, retigabine selectively enhances ex-
trasynaptic GABAA receptors that contain the δ- subunit.
108 
Thus, various lines of evidence raise the possibility that ef-
fects of retigabine on GABA mechanisms could be of impor-
tance in its antiseizure activity.102
Compared to other alkyl- carbamates that are used clini-
cally, the potential mechanisms of action of carisbamate have 
been less extensively studied (Table 3). Carisbamate has been 
reported to exert a use- dependent blocking action on voltage- 
gated Na+ channels in cultured hippocampal neurons,49 which 
is consistent with its inhibitory effect on repetitive action po-
tential firing in rat piriform cortical neurons.50 Furthermore, 
carisbamate appears to increase Cl− conductance presyn-
aptically and, under certain conditions, postsynaptically to 
selectively depress excitatory neurotransmission.50 These 
effects were blocked by picrotoxin, indicating an effect of ca-
risbamate on a picrotoxin- sensitive presynaptic GABAA- like 
Cl− conductance, but there is no evidence that carisbamate 
has any effect on spontaneous GABAA miniature inhibitory 
postsynaptic currents.50 Similarly, in dentate gyrus granule 
cells, carisbamate did not affect GABAergic transmission 
but depressed AMPA- and NMDA- receptor- mediated ex-
citatory neurotransmission.51 More recently, carisbamate 
was reported to inhibit T- type calcium channels.52 To our 
knowledge, detailed studies of carisbamate on synaptic ver-
sus extrasynaptic GABA responses are missing, as are studies 
on potential interaction with TBPS or TBOB binding to the 
GABAA receptor and experiments with recombinant GABAA 
receptors. As such, it is not possible, at this time, to conclude 
whether carisbamate has a similar or distinct mechanistic 
profile from other alkyl- carbamates.
Even fewer mechanistic studies are available for ceno-
bamate (Table 3), most likely because this novel ASD 
was only introduced in 2019. Two mechanisms of action 
emerge from the few published studies on cenobamate: (1) 
phenobarbital- like potentiation of synaptic and extrasynaptic 
GABAergic inhibition by a non- BDZ mode of action, and 
(2) an inhibitory effect at the INaP (Table 3). With respect to 
GABA, cenobamate acts as a PAM of GABAA receptors in 
hippocampal neurons, with effects on both phasic and tonic 
inhibitory currents and on recombinant synaptic and extra-
synaptic GABAA receptor isoforms, effects that were not an-
tagonized by the BDZ antagonist flumazenil.57 In line with 
a barbiturate- like effect, cenobamate has been reported to 
displace the binding of TBPS to the GABA- gated Cl− chan-
nel, whereas the binding of GABA, muscimol, flunitraze-
pam, and Ro- 15- 1788 (flumazenil) to GABAA receptors was 
not inhibited.47,109 Thus, as shown in Table 3, the effect of 
cenobamate on GABAA receptors resembles that of other 
T A B L E  3  Mechanisms of action of alkyl- carbamates with antiseizure activity
Compound
GABA- evoked responses Specific interaction with GABAA receptors Glutamatergic transmission Voltage- gated Na
+ channels
Voltage- gated Ca2+ 
channels








site (TBPS or TBOB 
binding) BDZ recognition site
Receptor activation  
in the absence of  







Meprobamate Enhanced Enhanced Inhibited Allosteric enhancement 
of BDZ binding
Yes Inhibited (only at high 
concentrations)
? ? ? ? ?
Felbamate Enhanced ? Inhibited No inhibition of BDZ 
binding
No Inhibited ? Use- dependent block ? Use- dependent block ?
Flupirtine Enhanced Enhanced ? ? ? No relevant effect ? No effect ? No effect Activated
Retigabine Enhanced Enhanced Inhibited ? ? No effect No effect Weak inhibition ? Weak inhibition Activated
Carisbamate No effect (but see 
text)
? ?
(but effect on picrotoxin- 
sensitive Cl− channels)
? ? Inhibited Inhibited Use- dependent block ? Inhibition ?
Cenobamate Enhanced Enhanced Inhibited No inhibition of BDZ 
binding
? ? ? Little effect (IC50 > 
500 µmol·L– 1)
Block ? ?
Phenobarbital Enhanced Enhanced Inhibited Allosteric enhancement 
of BDZ binding
Yes No effect Inhibited No relevant effect ? Use- dependent block ?
Note:: Phenobarbital is shown for comparison. "?" indicates that no data were found in the public domain. See text for references.
Abbreviations: AMPA, α- amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic acid; BDZ, benzodiazepine; GABA, γ- aminobutyric acid; IC50, median effective dose;  
KCNQ, voltage gated Kv7 potassium channels; NMDA, N- methyl- D- aspartate; TBOB, [3H]t- butylbicycloorthobenzoate; TBPS, [35S]t- butylbicyclophosphorothionate
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alkyl- carbamates and phenobarbital. With respect to voltage- 
gated Na+ channels, cenobamate inhibits the noninactivating 
INaP more potently than the transient Na
+ current,56 which 
likely contributes to the ability of this drug to suppress sus-
tained depolarizations while sparing single action potentials 
and low- frequency firing. Furthermore, cenobamate was 
shown to enhance the inactivated state of voltage- gated Na+ 
channels.56 Notably, these reported effects of cenobamate on 
both GABAA receptors and on the INaP appear to occur at 
very similar concentrations.
Under normal physiological conditions, depolarization of 
the neuronal cell membrane leads to a transient inward Na+ 
current (INaT) that rapidly inactivates. However, a small pro-
portion of Na+ channels appear to undergo rare, late openings 
in response to depolarization and give rise to a Na+ current 
(INaP) that fails to inactivate, and is thereby termed “per-
sistent.”110 INaPs, despite their small amplitude in comparison 
to transient currents, play a disproportionately large role in 
the regulation of neuronal excitability and repetitive firing 
capabilities,110 and their existence is relevant to the phar-
macology of several ASDs.19 Substantial block of the INaP 
is observed with phenytoin at therapeutically relevant con-
centrations (conductance reduced to 20%– 22% of control), 
which exceeds the effect of the drug on the transient current 
(reduced to 40%– 41% of control) that underlies normal ac-
tion potential generation.111,112 Partial block of the INaP is also 
observed with carbamazepine (~55% of control) and topira-
mate (~70% of control), with potencies that can approximate 
(carbamazepine) or even exceed (topiramate) their effects 
on INaT.
110,113 Valproate has also been shown to block INaP at 
concentrations within the therapeutic range,114 whereas etho-
suximide does so only at supratherapeutic levels.115 Thus, 
cenobamate is not the only ASD that inhibits the INaP, but, 
to our knowledge, it is the only alkyl- carbamate for which an 
effect on INaP has been reported to date. Its ability to produce 
a substantial block of INaP (31.5% of control at 100 µmol·L
– 1), 
together with the clear separation in concentrations at which 
it blocks persistent (IC50 = 53.1 µmol·L
– 1) versus transient 
(IC50 > 500 µmol·L
– 1) Na+ currents,56 may set it apart from 
most other ASDs that share this mechanism.
An inherent problem when comparing mechanisms of ac-
tion of alkyl- carbamates and phenobarbital (Table 3) is the 
lack of “head- to- head” studies in the same preparation. One 
of the few exceptions is the comparison of meprobamate and 
felbamate on GABA- evoked responses in rat hippocampal 
neurons reported by Rho et al.96 Several of the mechanisms 
illustrated in Table 3 have not been examined for all alkyl- 
carbamates, at least in part because the respective techniques 
were not available at the time at which some of these drugs 
were first developed and characterized. Thus, for instance, 
we simply do not know whether cenobamate differs in its ef-
fects on Na+ channels from other alkyl- carbamates. For ceno-
bamate, it has been suggested that the INaP may be a critical 
target for enhanced seizure control, especially when com-
bined with a PAM effect that can enhance GABAA currents 
and subsequent inhibitory neurotransmission.55 However, as 
shown in Tables 1 and 2, the preclinical antiseizure profile of 
cenobamate is very similar to that of other alkyl- carbamates, 
particularly the monocarbamates retigabine and carisbamate, 
for which there is no information about effects on INaPs. 
As shown in Table 3, the only common mechanistic effect 
of most, if not all, alkyl- carbamates is a phenobarbital- like 
enhancement of GABA responses.
It is possible that the combined (and perhaps synergistic) 
effect of cenobamate on GABA- mediated inhibition and on 
INaP, which occur at similar concentrations, contributes to its 
broad antiseizure profile and impressive clinical efficacy,55 
but this mechanistic profile is not unique. It is also shared, 
at least in part, by topiramate,19 a drug that has a different 
efficacy profile in preclinical models. These differences may 
be explained by the additional cellular effects of topiramate 
(i.e., on Ca2+ channels and ionotropic glutamate receptors) 
that are not, to our knowledge, observed with cenobamate55 
but perhaps also by differences in the extent to which each 
drug can block INaP. Then again, given the current dearth of 
mechanistic information, we cannot rule out the possibility of 
other, as yet unknown mechanisms that additionally contrib-
ute to the antiseizure activity of cenobamate.
6 |  CLINICAL EFFICACY OF 
ALKYL - CARBAMATES IN PATIENTS 
WITH DRUG- RESISTANT FOCAL 
EPILEPSY
Achieving seizure freedom is the primary goal in the treat-
ment of epilepsy; however, at least 30% of patients do not 
become seizure- free on existing ASDs, with even higher fig-
ures in patients with focal epilepsy.116 Thus, all new ASDs 
are initially evaluated as add- on treatment for patients with 
seizure disorders that are not adequately controlled with one 
or more standard agents.117,118
One of the most common primary outcome measures in 
randomized controlled trials (RCTs) aimed at demonstrating 
efficacy and safety of a new ASD is the percentage of sub-
jects who experience a 50% or greater reduction in seizure 
frequency from baseline (i.e., the so- called “responder rate”). 
Until recently, seizure freedom was not generally quoted as 
a primary outcome measure in RCTs, largely because of the 
refractoriness of epilepsy in this population and limited ex-
pectation of achieving complete remission over the short trial 
period.118,119 Thus, prior to the year 2000, few clinical trials 
adopted this indicator, and although more recent RCTs have 
explored seizure freedom as an outcome, they have typically 
shown very modest remission rates, varying from 1% to 5%, 
despite the chemical and pharmacological diversity of the 
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drugs studied.120- 122 A recent meta- analysis122 of seizure free-
dom across 40 RCTs of ASDs in a total of 9136 patients with 
drug- refractory focal epilepsy found that eight ASDs (includ-
ing the alkyl- carbamates carisbamate and retigabine) were 
superior to placebo, the most effective being brivaracetam, 
with a reported remission rate of 4%– 5%.123 This observation 
supports an earlier study of 63 pivotal RCTs of lamotrigine, 
gabapentin, topiramate, tiagabine, levetiracetam, zonisamide, 
pregabalin, lacosamide, and eslicarbazepine, and also a 
pooled analysis of the three pivotal trials conducted for both 
perampanel and brivaracetam, in which seizure- free rates 
ranged from 0% to a maximum of 6.5%.124,125 By contrast, 
a recent Phase 2b trial of cenobamate in patients with drug- 
refractory focal epilepsy reported seizure- free rates over the 
12- week maintenance period ranging from 4% at 100  mg/
day to 21% at 400 mg/day, compared to just 1% in the pla-
cebo arm.58 A further Phase 2 study reported 28% remission 
with cenobamate at 200 mg/day compared to 9% for placebo, 
albeit over a shorter, 6- week maintenance period.126 Thus, 
the degree of seizure freedom associated with higher doses 
of cenobamate was well beyond that seen for any new ASD 
brought to the market in the past 25 years.125 By way of com-
parison, felbamate, which was considered highly effective, 
was associated with a remission rate of 10% in 246 patients 
with drug- refractory focal epilepsy.127
If cenobamate maintains its high seizure- free rate in 
long- term use, then it may represent an important new ASD. 
However, regulatory trials involve a carefully selected popu-
lation of patients and are conducted under rigorously stan-
dardized conditions, so data from such studies often cannot 
be translated into clinical practice.119 For cenobamate, results 
from open- label extension (OLE) studies suggest that its ef-
ficacy is sustained for at least the first 3 years of treatment, 
remaining consistent with the level of effect observed in the 
double- blind, placebo- controlled trials.128 Importantly, the 
remission rate during the last 6 months of follow- up (Months 
25– 30) was 20.2% of all evaluable patients. Among the patients 
who were seizure- free at Months 25– 30, the median duration of 
seizure freedom during the entire OLE phase was 33.2 months.
This impressive efficacy emerging from recent RCTs with 
cenobamate is, however, tempered by the risk of serious rash 
(i.e., DRESS) and low tolerability at higher doses,58 meaning 
that further safety studies and clinical experience are needed 
to determine the true clinical value of cenobamate.9
7  |  RISK OF SEVERE 
IDIOSYNCRATIC ADVERSE 
EVENTS WITH DIFFERENT 
ALKYL -  CARBAMATES
As described above, both meprobamate and felbamate have 
been reported to induce rare but fatal idiosyncratic adverse 
effects, namely, aplastic anemia and liver toxicity in pa-
tients. For felbamate, it has been proposed that an alterna-
tive metabolic pathway, which involves the formation of 3- 
carbamoyl- 2- phenylpropionaldehyde as a potentially reac-
tive intermediate, contributes to its bioinactivation.10,24,129 In 
vitro, the aldehyde undergoes rapid facile elimination to form 
2- phenylpropenal (atropaldehyde) and can also be cyclized 
to form the more stable 4- hydroxy- 5- phenyltetrahydro- 1,3
- oxazin- 2- one, which may act as a reservoir of the reactive 
aldehyde.130 The atropaldehyde metabolite is electrophilic 
and cytotoxic, and its formation has been confirmed in vivo 
in rodents and humans, suggesting that it may be responsible 
for felbamate- induced liver and bone marrow toxicity.10,129 
Under normal conditions, atropaldehyde is rapidly conju-
gated with glutathione, which acts as a protective mechanism 
by inactivating atropaldehyde before it can cause damage.24 
Most patients will maintain sufficient levels of glutathione to 
detoxify the reactive metabolite of felbamate.25 Those with a 
history of felbamate- associated aplastic anemia had signifi-
cantly lower erythrocyte glutathione peroxidase levels,10 and 
clinical studies with felbamate have demonstrated an associa-
tion between reactive metabolite formation and clinically rel-
evant toxicity.24 Possible risk factors for felbamate- associated 
aplastic anemia include history of cytopenia, prior history of 
autoimmune disorder, and a positive antinuclear antibody 
titer.10 Although the use of felbamate has been restricted, this 
drug remains an effective and safe treatment for patients with 
seizures refractory to other ASDs when used in accordance 
with existing recommendations and with close clinical moni-
toring.10,23,25 Evidence for a key role of reactive metabolites 
in felbamate toxicity provided a rationale for the development 
of fluorofelbamate (MedPointe Pharmaceuticals), a felbamate 
analogue that is not converted to atropaldehyde.131
Flupirtine is another example of an alkyl- carbamate that 
induces rare but potentially fatal idiosyncratic liver toxicity, 
a characteristic it does not seemingly share with the structur-
ally similar drug retigabine.13 Even after more than 30 years 
of use, the hepatotoxicity of flupirtine is still poorly under-
stood. As with felbamate, a probable toxification mechanism 
of flupirtine has been described, caused by extensive oxida-
tion by peroxidase enzymes and leading to the generation of 
unstable intermediates with the potential to interact with nuc-
leophilic moieties, such as thiol- containing cysteine residues, 
and thereby covalently modify liver proteins.13 Presumably, 
in healthy subjects, the reactive quinone diimines are inter-
cepted again by glutathione, but under conditions of glutathi-
one depletion, as are often found in the elderly, these reactive 
metabolites might react with liver proteins leading to hep-
atotoxicity. Unlike flupirtine, retigabine is not substantially 
metabolized via oxidation but rather undergoes Phase II re-
actions.13 This difference in metabolic profile might explain 
the differences in hepatotoxic potential between these struc-
turally similar drugs.
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Although retigabine is seemingly devoid of the potential 
to cause idiosyncratic liver toxicity, within 2 years of retiga-
bine's approval for clinical use, multiple cases of blue discol-
oration of the tissues began to emerge.132 The hard palate, 
nails, lips, and the conjunctiva were particularly affected, 
often years after initiation of retigabine therapy, and retinal 
pigmentations raised concerns about possible vision loss.13 
The FDA subsequently recommended eye examinations 
every 6  months and discontinuation of the drug when eye 
discolorations were observed. The incidence rate of tissue 
discoloration is reported to be 3.6% per patient- year, with a 
median onset of approximately 4 years.13 In biopsy samples 
of discolored tissue, dimers of retigabine and dimers of its 
main metabolite were found, partly in conjunction with mel-
anin.13 These dimers might be responsible for the abnormal 
pigmentation under retigabine treatment, which is considered 
an idiosyncratic adverse event.
Available evidence to date suggests that neither caris-
bamate nor cenobamate undergo biotransformation into 
reactive metabolites. The major metabolic pathways of ca-
risbamate in humans are direct O- glucuronidation (44% of 
the dose), and hydrolysis of the carbamate ester followed by 
oxidation to 2- chloromandelic acid, which is subsequently 
metabolized in parallel to 2- chlorophenyl glycine and 
2- chlorobenzoic acid.133 Only traces of aromatic (pre)mer-
capturic acid conjugates have been detected in the urine (each 
<.3% of the dose), suggesting a low potential for reactive 
metabolite formation. Cenobamate is metabolized by both 
cytochrome P450 (CYP) and uridine 5’- diphosphoglucuron
osyltransferase (UGT) enzymes.134 Multiple CYP enzymes 
have appeared to be involved in cenobamate metabolism, 
with CYP2E1, CYP2A6, and CYP2B6 as the major enzymes 
contributing to oxidative metabolism in humans and, to a 
lesser extent, CYP2C19 and CYP3A4/5.134 Glucuronidation 
of cenobamate is predominantly catalyzed by UGT2B7 and, 
to a lesser extent, by UGT2B4.
Despite an apparently benign metabolic profile, the 
early clinical development of cenobamate, during which 
the drug was titrated quickly, witnessed three cases of 
idiosyncratic DRESS among the first 953 individuals ex-
posed to the drug, including one fatality.9 In the RCT by 
Krauss et al.,58 which also employed a rapid titration rate, 
three of 437 participants experienced hypersensitivity re-
actions, one of which was DRESS. As a result, DRESS is 
among the warnings and precautions for cenobamate in the 
US prescribing information. Interestingly, a further large- 
scale safety study that employed a slower titration rate than 
previous studies, with a start- low (12.5 mg/day), go- slow 
approach, reported no cases of DRESS among 1339 par-
ticipants.59 As is the case for several other ASDs, it would 
appear that safety concerns with cenobamate can be at 
least partly mitigated by cautious titration. Nevertheless, 
the number of cenobamate- exposed patients worldwide 
remains too low to assess the true risk of rare but serious 
idiosyncratic events with this drug.
With respect to the idiosyncratic adverse reactions de-
scribed above for cenobamate, it has to be considered that 
cutaneous manifestations of hypersensitivity are the most 
common idiosyncratic reactions associated with ASD use 
and are independent of their antiseizure mechanisms of ac-
tion.129,135,136 Skin rashes in the vast majority of people are 
mild in severity, but serious and potentially life- threatening 
reactions, such as DRESS, Stevens– Johnson syndrome, and 
toxic epidermal necrosis can occur on occasion. Aromatic 
ASDs such as carbamazepine, oxcarbazepine, eslicarbaze-
pine acetate, phenytoin, lamotrigine, phenobarbital, prim-
idone, and zonisamide are all associated with idiosyncratic 
skin reactions, whereas alkyl- carbamates are less frequently 
implicated.136
8 |  DEVELOPMENT OF NEW 
ALKYL - CARBAMATES WITH 
ANTISEIZURE EFFICACY
The success of alkyl- carbamates as ASDs has prompted 
intensive research with the goal of developing novel com-
pounds with lowered risk of severe idiosyncratic adverse 
effects. One example, already noted above, is fluorofel-
bamate, which was designed to retain the broad spectrum 
multimechanistic activity of felbamate, with a modified 
metabolism that has been shown to avoid the production 
of the reactive atropaldehyde metabolite believed to cause 
its idiosyncratic toxicity.131 Similarly, flupirtine and reti-
gabine are being used as templates for ligand- based drug 
design of KV7.2/3 activators,
13,137,138 although such agents 
are predominantly being developed for the treatment of 
neuropathic pain, which represents a potentially bigger 
and less- crowded market. Nevertheless, modulation of the 
KV7.2/3 heterotetramer has potential for efficacy in nu-
merous indications related to hyperexcitability,13 and, as 
such, these novel compounds are also interesting candi-
dates for epilepsy.28 Apart from KV7.2/3 selective activa-
tors, several other series of alkyl- carbamates, comprising 
hundreds of compounds, have been synthesized and tested 
for antiseizure activity.2,139- 146 Among the numerous alkyl- 
carbamates tested, chiral CNS- active carbamate deriva-
tives of valproic acid were particularly interesting.143
9 |  CONCLUSIONS
As a class, alkyl- carbamate drugs have long attracted inter-
est for their potential efficacy in the treatment of epilepsy, 
from the first report of the anticonvulsant effects of meproba-
mate14 to the recent development and FDA approval in 2019 
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of cenobamate.9 Two distinct groups of alkyl- carbamates 
exist: the dicarbamates, which include meprobamate and 
felbamate; and the monocarbamates, which include flupir-
tine, retigabine, carisbamate, and cenobamate. All alkyl- 
carbamates have efficacy in a range of preclinical models, 
and most have demonstrated clinical utility in either RCTs 
or in the routine management of seizure disorders, with only 
modest differences in their spectra of activity. Some have ad-
ditionally shown promise in the epileptic encephalopathies 
and in other, nonepilepsy indications. Most alkyl- carbamates 
(with the possible exception of carisbamate) appear to share 
a common mechanism, involving positive allosteric modu-
lation of the GABAA receptor in a barbiturate- like manner, 
which often includes effects at both synaptic and extrasynap-
tic receptor sites that mediate phasic and tonic Cl− currents, 
respectively. They appear to diverge in terms of additional 
mechanisms of action, which include potentiation of Kv7- 
mediated voltage- gated K+ currents (flupirtine, retigabine), 
inhibitory effects on ionotropic glutamate receptors (fel-
bamate, carisbamate), and blockade of both transient Na+ 
currents (felbamate, carisbamate) and INaPs (cenobamate).
The latest alkyl- carbamate to be approved for epilepsy— 
cenobamate— appears to possess an unprecedented capacity 
to elicit seizure freedom under the admittedly artificial con-
ditions of regulatory RCTs. Remission rates in cenobamate 
trials have exceeded those of all other ASDs approved in the 
past 25 years by a factor of three- to fourfold and appear to 
be sustained in longer term follow- up. One possible expla-
nation is cenobamate's unique combination of mechanisms 
of action, comprising both positive allosteric modulation 
of the GABAA receptor at a non- BDZ site and preferential 
blockade of the persistent current carried by voltage- gated 
Na+ channels, and potential synergy between these cellular 
effects. Both actions occur at similar concentrations, and al-
though this mechanistic profile is shared, in part, with the 
sulfamate- substituted monosaccharide topiramate, they dif-
fer markedly in the extent of INaP block and in their preclin-
ical antiseizure profile. It remains to be seen whether the 
apparent efficacy of cenobamate is sustained during routine 
clinical use and also whether the idiosyncratic reactions that 
have often blighted this class of ASD and that were evident 
in some cenobamate trials, have an impact on its effective-
ness in the real world.
Irrespective of the longer term outlook for cenobamate, 
the alkyl- carbamates will continue to represent an inter-
esting class of compounds, with powerful antiseizure ac-
tions in experimental models and common forms of human 
epilepsy and with the potential to offer hope in otherwise 
drug- resistant epileptic encephalopathies and as precision 
therapies. That expectation potentially comes at the price 
of rare adverse reactions that can be severe and occasion-
ally fatal but that may be surmountable with careful dosing 
and patient monitoring.
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